Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.72 |
| ▸ | TP53 | P04637 | 12/20 | 0.72 |
| ▸ | TLR9 | Q9NR96 | 8/20 | 0.72 |
| ▸ | NPC1 | O15118 | 8/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.72 |
| ▸ | HTT | P42858 | 3/20 | 0.72 |
| ▸ | XBP1 | P17861 | 3/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | MITF | O75030 | 2/20 | 0.53 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2475444 | 0.82 | TP53 (0.64) | MAPTTP53TLR9NPC1ALDH1A1 | |
| SCHEMBL28283383 | 0.81 | TLR9 (0.49) | MAPTTP53TLR9NPC1ALDH1A1 | |
| SCHEMBL15286672 | 0.81 | MAPT (0.62) | MAPTTP53TLR9NPC1ALDH1A1 | |
| SCHEMBL22366819 | 0.78 | NPSR1 (0.48) | MAPTTP53TLR9NPC1ALDH1A1 | |
| SCHEMBL23879945 | 0.78 | MAPT (0.59) | MAPTTP53TLR9NPC1ALDH1A1 | |
| SCHEMBL23879946 | 0.78 | MAPT (0.68) | MAPTTP53TLR9NPC1ALDH1A1 | |
| SCHEMBL26287659 | 0.77 | NPSR1 (0.47) | MAPTTP53TLR9NPC1ALDH1A1 | |
| SCHEMBL11288067 | 0.76 | NPSR1 (0.45) | MAPTTP53TLR9NPC1ALDH1A1 | |
| SCHEMBL28223670 | 0.76 | NPSR1 (0.45) | MAPTTP53TLR9NPC1ALDH1A1 | |
| SCHEMBL29037763 | 0.75 | TP53 (0.69) | MAPTTP53TLR9NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116456985-A | Pyrimidine and pyridine derivatives as HPK1 modulators and methods of use thereof | 深圳市原力生命科学有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20110118126-A1 | METHODS OF CHEMOTYPE EVOLUTION | SUNESIS PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118126-A1 | METHODS OF CHEMOTYPE EVOLUTION | SUNESIS PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| WO-2009120795-A1 | METHODS OF CHEMOTYPE EVOLUTION | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090227612-A1 | Aminopyrimidine Derivatives Inhibiting Protein Kinase Activity, Method For The Preparation Thereof And Pharmaceutical Composition Containing Same | CRYSTALGENOMICS, INC. (KP) | 2009-09-10 | — | — | US | disclosed |
| CN-101346356-A | Aminopyrimidine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same | CRYSTALGENOMICS INC (KR) | 2009-01-14 | — | — | CN | disclosed |
| EP-1973885-A1 | AMINOPYRIMIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Crystalgenomics, Inc. (KR) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007073117-A1 | AMINOPYRIMIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-06-28 | — | — | WO | disclosed |
| EP-0033195-B1 | PYRIMIDINE-2-SULPHIDES AND THEIR S-OXIDES FOR USE IN MEDICINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCESSES FOR THEIR PREPARATION AND SUCH COMPOUNDS WHEN NOVEL PER SE | NYEGAARD & CO. A/S (NO) | 1985-12-04 | — | — | EP | disclosed |
| US-4423047-A | INHIBITING ABNORMAL CELL PROLIFERATION | NYEGAARD & CO. A/S (NO) | 1983-12-27 | — | — | US | disclosed |
| EP-0033195-A1 | Pyrimidine-2-sulphides and their S-oxides for use in medicine, pharmaceutical compositions containing them, processes for their preparation and such compounds when novel per se | NYEGAARD & CO. A/S (NO) | 1981-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227612-A1 | Aminopyrimidine Derivatives Inhibiting Protein Kinase Activity, Method For The Preparation Thereof And Pharmaceutical Composition Containing Same | GSK3B, GSK3A, MAP3K1 | MAPT 98/4885TP53 322/4885TLR9 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.